Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality. |
| |
Authors: | W Lesslauer H Tabuchi R Gentz M Brockhaus E J Schlaeger G Grau P F Piguet P Pointaire P Vassalli H Loetscher |
| |
Affiliation: | F. Hoffmann-La Roche Ltd., Basel, Switzerland. |
| |
Abstract: | The in vivo efficacy of human recombinant soluble tumor necrosis factor (TNF) receptor protein to prevent and to treat lipopolysaccharide (LPS)-induced lethal toxicity in D-galactosamine-treated mice was investigated. Chimeric proteins of the receptor extracellular domains fused to the hinge region of human IgG3 were expressed in myeloma cells (rsTNFR-h gamma 3). The fusion proteins had a disulfide-bonded dimeric structure. Upon intravenous injection, their serum concentration decreased relatively slowly after an initial phase of rapid elimination. D-galactosamine-sensitized mice were fully protected from the toxic effects of LPS, if the animal were pretreated with rsTNFR-h gamma 3 at 20 micrograms/animal. Partial protection was seen at significantly lower doses and when rsTNFR-h gamma 3 was given up to 3 h after LPS. |
| |
Keywords: | |
|
|